ICUI
ICU Medical, Inc.
ICUI's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over ICUI overall, supported by stronger valuation and stronger fundamentals.
ICUI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Stable |
ICUI's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ICUI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 19x | $177 | — |
| Cheap | 46x | $110 | -38% |
| Fair | 52x | $124 | -30% |
| Current | 74x | $177 | — |
| Expensive | 136x | $325 | +83% |
Historical ranges are pointers, not guarantees.
ICUI has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ICUI Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for ICUI, with profitability improving.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ICUI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.19 | +283% |
| Q3 2026 | $2.40 | +$2.71 |
| Q2 2026 | $1.19 | +$2.71 |
| Q1 2026 | $1.86 | +$5.69 |
| Q4 2025 | $0.03 | +$4.86 |
| Q3 2025 | -$0.31 | +$4.26 |
| Q2 2025 | -$1.52 | +$1.40 |
| Q1 2025 | -$3.83 | -$1.38 |
| Q4 2024 | -$4.83 | -$3.60 |
ICUI has returned to profit: it earned $2.40 per share over the past year, after losing money the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ICUI on earnings, with more consistent year-over-year improvement.
ICUI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $560.4M | +4.4% |
| Q2 2026 | $551.7M | +0.5% |
| Q1 2026 | $530.2M | -12% |
| Q4 2025 | $540.7M | -14% |
| Q3 2025 | $537M | -8.9% |
| Q2 2025 | $548.9M | -8% |
| Q1 2025 | $604.7M | +6.7% |
| Q4 2024 | $629.8M | +7.1% |
ICUI's revenue is down over the past year, though its latest quarter was up: $560M last quarter, up 4.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.3% | +6.8 points |
| Q2 2026 | 7.1% | +5.2 points |
| Q1 2026 | 2.6% | +0.4 points |
| Q4 2025 | 1% | -4.9 points |
| Q3 2025 | 2.5% | +1.1 points |
| Q2 2025 | 1.9% | +0.6 points |
| Q1 2025 | 2.1% | +4 points |
| Q4 2024 | 6% | +8.1 points |
ICUI's operating margin was 9.3% last quarter, up 6.8 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ICUI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ICUI on profitability, with a higher operating margin.
ICUI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $83.4M | +202% |
| Q2 2026 | $61.6M | +$70.1M |
| Q1 2026 | $27.6M | -25% |
| Q4 2025 | $36M | +123% |
| Q3 2025 | $27.6M | +71% |
| Q2 2025 | -$8.5M | -114% |
| Q1 2025 | $36.7M | +23% |
| Q4 2024 | $16.1M | -74% |
ICUI generated $209M in free cash flow over the past year, up 190% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ICUI on cash flow, with more consistent year-over-year improvement.
ICUI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +101K shares |
| 1 year | +1.9% | +459K shares |
| 3 years | +3.2% | +777K shares |
| 5 years | +16% | +3.4M shares |
| Available history | +17% | +3.6M shares |
ICUI has 25M diluted shares, up 1.9% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ICUI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ICUI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.7x | Moderate |
| Q2 2026 | 3.4x | Elevated |
| Q1 2026 | 4.1x | High |
| Q4 2025 | 4.0x | High |
| Q3 2025 | 3.7x | Elevated |
| Q2 2025 | 3.7x | Elevated |
| Q1 2025 | 4.5x | High |
| Q4 2024 | 4.9x | High |
ICUI's net debt is about 2.7 years of its operating earnings (EBITDA), down from 3.6 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over ICUI on leverage, with a lower net debt burden relative to earnings.
ICUI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 62.4 | Neutral |
| Stochastic | 49.5 | Neutral |
ICUI's weekly RSI is 62 (neutral) and its Stochastic is 49 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ICUI PE vs Healthcare Sector
| Metric | ICUI | Sector median | Relative |
|---|---|---|---|
| PE | 74x | 26x | 186% above |
| PE % | 70 | 29 | 41 pts above |
ICUI is trading at 74x earnings, a 186% premium to the Healthcare sector's median of 26x.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY has the edge over ICUI on valuation relative to its sector.
ICUI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $165.9 | 6.9% above |
| 20 week MA | $166.1 | 6.7% above |
| 50 week MA | $149.5 | 19% above |
| 100 week MA | $143.8 | 23% above |
| 200 week MA | $141.8 | 25% above |
ICUI is in an uptrend: it's above all five of its weekly moving averages, and 25% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
ICUI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $186.2 | $211.7 | +14% |
| 2021 | $211.7 | $235.7 | +11% |
| 2022 | $235.7 | $156.0 | -34% |
| 2023 | $156.0 | $99.7 | -36% |
| 2024 | $99.7 | $154.5 | +55% |
| 2025 | $154.5 | $147.9 | -4.3% |
| 2026 YTD | $147.9 | $177.3 | +20% |
ICUI has finished lower in three of the last six years. It's up 20% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ICUI on returns for 2026, with the stronger performance.